Cristina Garcia

Grupo de investigación

Endocarditis. Infecciones cardiovasculares. Modelo experimental Accredited researcher (R3A)

cgarciad@recerca.clinic.cat 0000-0002-0585-9469

Sobre mí

La Dra. Cristina García de la Mària es investigador del IDIBAPS y ha sido la coordinadora del Laboratorio de Endocarditis Experimental durante los últimos dieciocho años. Dirige y realiza, junto con el resto del equipo del laboratorio de endocarditis experimental, los estudios in vitro e in vivo de los diferentes modelos descritos en las líneas de investigación del grupo. También es responsable de la dirección y formación en el laboratorio de los alumnos de máster y predoctorales así como de investigadores en estancias postdoctorales. Ha publicado 68 artículos en revistas de revisión por pares y lleva a cabo la coordinación de los Work in Progress y Journal Club de las sesiones semanales del Endocarditis Team.

Publicaciones destacadas

Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report

Autores:
Duss FR; Garcia de la Mària C; Croxatto A; Giulieri S; Lamoth F;

Manuel O; Miró JM .

Referencia: Journal Of Antimicrobial Chemotherapy 2019.
AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis.

Autores:
Castañeda X; García-de-la-Mària C; Gasch O; Pericas JM; Armero Y;

(...)

Soto S; Moreno A; Marco F; Miró JM; Hospital Clinic Endocarditis Study Group.

Referencia: Antimicrobial Agents And Chemotherapy 2017.
Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis.

Autores:
Pericàs JM; Messina JA; Garcia-de-la-Mària C; Park L; Sharma-Kuinkel BK;

(...)

Chu VH; Moreno A; Fowler VG; Miró JM; International Collaboration on Endocarditis Microbiology Investigators.

Referencia: Clinical Microbiology And Infection 2017.
Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.

Autores:
Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J;

(...)

Llopis J; Marco F; Moreno A; Miró JM; Hospital Clinic Endocarditis Study Group.

Referencia: Journal Of Antimicrobial Chemotherapy 2017.
Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Autores:
Garcia-de-la-Maria C; Xiong YQ; Pericas JM; Armero Y; Moreno A;

(...)

Tran TT; Arias CA; Sullam PM; Bayer AS; Miro JM .

Referencia: Antimicrobial Agents And Chemotherapy 2017.
Fosfomycin plus beta-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus

Autores:
del Rio, A; Garcia-de-la-Maria, C; Entenza, JM; Gasch, O; Armero, Y;

(...)

Gatell, JM; Moreno, A; Moreillon, P; Marco, F; Miro, JM.

Referencia: Antimicrobial Agents And Chemotherapy 2016.

Proyectos destacados

Prevention of vascular catheter-related infections by the FUNctionalization of CATHeters with thermically activated hydrogels with antimicrobial agents of broad spectrum (FUNCATH).

Investigador/a principal: Cristina Garcia de la Maria

Financiador: Fundació La Marató de TV3

Código: 75/C/2018

Duración: 15/01/2019 - 31/12/2022
In vitro and experimental endocarditis model study of the efficacy of new oral and parenteral combinations of antibiotics for outpatient treatment of infectious endocarditis

Investigador/a principal: José Maria Miró Meda

Financiador: ISCIII (Participante)

Código: PI 20/00830

Duración: 01/01/2021
Staphylococcus aureus sensitivity to CF-301 Lysin in an in vitro study by Broth Microdilution Method.

Investigador/a principal: Josep M. Miró Meda

Financiador: ContraFect Corporation

Duración: 01/03/2019
Estudio de la eficacia de daptomicina asociada a otros antibióticos en el tratamiento de la endocarditis experimental por Staphylococcus aureus resistente o no a meticilina (SARM/SASM) y Staphylococcus epidermidis resistentes a meticilina (SERM) y a vancomicina (VRSE)

Investigador/a principal: Jose Maria Miro Meda

Financiador: Fundació Privada Clínic per a la Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos III

Duración: 01/01/2011 - 31/12/2013
To evaluate wether the combination of gentamicin and daptomycin (at doses of 6 mg/ kg or 10 mg/Kg) prevents the development of daptomycin resistance in the treatment of experimental endocarditis in rabbits infected with a penicillin-resistant Streptococcus mitis strain that develops a high level of daptomycin resistance when daptomycin is given in monotherapy.

Investigador/a principal: Jose Maria Miro Meda

Financiador: Cubist Pharmaceutical ; Fundació Privada Clínic per a la Recerca Biomèdica (Participante)

Duración: 01/01/2011

Cristina Garcia

Grupo de investigación

Sobre mí

Publicaciones destacadas

Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report

AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis.

Influence of Vancomycin Minimum Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis Treated with Anti-staphylococcal Beta-Lactam Antibiotics; a Prospective Cohort Study by the International Collaboration on Endocarditis.

Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Fosfomycin plus beta-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus

Proyectos destacados

Prevention of vascular catheter-related infections by the FUNctionalization of CATHeters with thermically activated hydrogels with antimicrobial agents of broad spectrum (FUNCATH).

In vitro and experimental endocarditis model study of the efficacy of new oral and parenteral combinations of antibiotics for outpatient treatment of infectious endocarditis

Staphylococcus aureus sensitivity to CF-301 Lysin in an in vitro study by Broth Microdilution Method.

Estudio de la eficacia de daptomicina asociada a otros antibióticos en el tratamiento de la endocarditis experimental por Staphylococcus aureus resistente o no a meticilina (SARM/SASM) y Staphylococcus epidermidis resistentes a meticilina (SERM) y a vancomicina (VRSE)

Suscríbete a la Newsletter del Clínic